A Phase 3 interventional study of Acetylsalicylic acid (Aspirin, BAY1019036) and Acetaminophen in Headache, sponsored by Bayer. Terminated at 1 site in United States. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2018-12-19.
Sponsored by Bayer · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 324 studies in Headache with a site in United States — 51 open to participants now, 63 under way, 5 of them phase 3. Headache · United States.
Among the 324 studies in Headache with a site in United States, this one is the 243rd largest by enrollment of the 276 interventional ones that give a count, is one of 19 that started in 2012, is one of 46 in phase 3, and was the 92nd registered.
762 studies on the registry are indexed under Headache; 134 are open to participants now.
Browse Headache studies →51 of the 324 studies in Headache with a site in United States are open now. Recruiting first, the newest first:
Salvia BioElectronics · Sites in United States
Ages 22–84
University of Colorado, Denver · Sites in United States
Ages 12–17
Daniel A Tonetti, MD · Sites in United States
Ages 18+
Cortex Neurovascular · Sites in United States
Ages 18–64
Duke University · Sites in United States
Ages 18–60
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 83 Headache studies recruiting now, 30 (36%) set no upper age limit and 44 (53%) stop at 75 or younger; 10 take children under 18; 14 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
324 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 16 · Phase 2 55 · Phase 3 54 · Phase 4 37
First in 1994; this study’s year is marked. 19 started in 2012.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 9 is below the median of 65 across 560 interventional studies indexed under Headache.
Median enrollment 64 across the 276 interventional studies, 129 across the 47 observational. Of the 224 that completed or were terminated, 104 (46%) have results posted.
This tab as a report to print or save as PDF → With an account.
87 of 324 have an industry lead sponsor. The 10 most frequent:
Bayer is the lead sponsor of 1,674 studies on the registry; 51 are open to participants now.
Of its 214 completed or terminated interventional studies of FDA-regulated products, 132 (62%) have results posted.
Bayer has 3 studies filed under Headache — fewer than ten, so there is no comparison to draw.
19 of the studies in Headache with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06621329Phase 3University of California, DavisTransnasal Sphenopalatine Ganglion Block for Treatment of Acute Subarachnoid Hemorrhage Associated Headache | 2027-07 |
| NCT07116408Wright State UniversityIntranasal Sphenopalatine Ganglion Blockade for Headaches Following Aneurysmal Subarachnoid Hemorrhage | 2026-11 |
| NCT07309874Texas Tech University Health Sciences CenterEffect of Ultrasound-Guided Dry Needling Targeting Rectus Capitus Posterior Major on Individuals With Headaches | 2026-12-01 |
| NCT07725198Florida Gulf Coast UniversityImmediate Neuromuscular Responses of the Obliquus Capitis Inferior Following Upper Cervical Manual Therapy | 2027-01-01 |
| NCT07054801Daniel Raper, MBBSIA Lidocaine and Methylprednisolone for Headache Associated With Subarachnoid Hemorrhage | 2027-01-01 |
Add all 19 to your calendar (.ics) → With an account.
Among the 324 studies in Headache with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this trial is to determine if a single, oral dose of a fast release aspirin 1000 mg provides relief compared to acetaminophen 1000 mg and placebo in subjects with tension-type headache pain.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Acetylsalicylic acid (Aspirin, BAY1019036)
Drug: Acetaminophen
Drug: Placebo
2 x 500 mg fast release aspirin tablets (1000 mg) and 2 x placebo acetaminophen caplets
2 x 500 mg acetaminophen caplets (1000 mg) and 2 x placebo fast release aspirin tablets
2 x placebo acetaminophen caplets and 2 x placebo fast release aspirin tablets
Time to meaningful pain relief (defined as the time when the subject indicates pain relief that is meaningful to the subject)
Time frame: Up to 2 hours post-dose
Time to first perceptible relief
Is defined as the time when the subject presses the first stopwatch
Time frame: Up to 2 hours post-dose
Time to first perceptible relief confirmed
The subjects would meet this outcome if they answer "yes" when asked directly after stopping the first stopwatch, if they marked a "1" on the relief pain scale or if they stopped the 2nd stop watch.
Time frame: Up to 2 hours post-dose
Change from baseline in pain intensity score at different time points (on an 11-point Categorical Pain Intensity Scale, 0 = no pain, 10 = severe pain)
Time frame: At baseline, 30, 60, 90 and 120 minutes post-dose, and immediately prior to the use of any rescue medication
Pain Relief on 5-point Categorical Scale (0 = no relief, 1 = a little relief, 2 = some relief, 3 = a lot of relief, and 4 = complete relief)
Time frame: At 30, 60, 90 and 120 minutes post-dose, and immediately prior to the use of any rescue medication
Summed time weighted of Pain Intensity Differences (PID) scores over first hour (SPID0-1)
Time frame: Up to 1 hour
Summed time weighted of Pain Intensity Differences (PID) scores over 2 hours (SPID0-2)
Time frame: Up to 2 hours
Summed time weighted total pain relief scores over first hour (TOTPAR0-1)
Time frame: Up to 1 hour
Summed time weighted of Total Pain Relief Scores (TOTPAR) scores over 2 hours (TOTPAR0-2)
Time frame: Up to 2 hours
Summed, time weighted of Pain Relief and Pain Intensity Differences (PID) over first hour (SPRID0-1)
Time frame: Up to 1 hour
Summed, time weighted of Pain Relief and Pain Intensity Differences (PID) over 2 hours (SPRID0-2)
Time frame: Up to 2 hours
Time to first intake of rescue medication
Time frame: Up to 2 hours
Cumulative proportion of subjects taking rescue medication by time point
Time frame: Up to 2 hours
Global assessment of the investigational product as a pain reliever: 0 = poor, 1 = fair, 2 = good, 3 = very good or 4 = excellent
Time frame: At 2 hours post-dose or immediately before the first intake of rescue medication, whichever is earlier
Safety variable will be summarized using descriptive statistic based on adverse events collection
Time frame: Up to 5 days post-dose
Ran from Mar 2012 to primary completion in Jun 2012, 2 months.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Dec 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Aspirin